lapatinib — Medica

Breast cancer

Initial criteria

age ≥ 18 years
human epidermal growth factor receptor 2 (HER2)-positive disease
recurrent or metastatic disease
EITHER:
Used in combination with capecitabine or trastuzumab AND patient has tried at least three prior anti-HER2 based regimens (examples include pertuzumab + trastuzumab + docetaxel, pertuzumab + trastuzumab + paclitaxel, fam-trastuzumab deruxtecan-nxki, ado-trastuzumab emtansine, tucatinib + trastuzumab + capecitabine)
OR used in combination with an aromatase inhibitor (letrozole, anastrozole, or exemestane) AND hormone receptor-positive (ER+ and/or PR+) AND ONE of the following: postmenopausal woman OR pre/perimenopausal woman receiving ovarian suppression/ablation with a GnRH agonist/surgical oophorectomy/ovarian irradiation OR man receiving a GnRH analog

1 year